Stocks360

LungLife AI, Inc. (LLAI.L)

Stock analysis · LSE · Healthcare · Medical - Diagnostics & Research

Share: Facebook X WhatsApp SMS

Get deeper signals and personalized alerts

Free account signup in under 60 seconds

Create free account → I already have an account
Market Cap
N/A
PE (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
Beta
0.37
Day Range
N/A
52-wk Range
N/A
Avg Volume
N/A
Volume
N/A

LungLife AI, Inc. (LLAI.L) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About LungLife AI, Inc.

LungLife AI, Inc. is a clinical diagnostics enterprise focused on creating AI-powered solutions for detecting lung cancer. The company is actively developing LungLB, an advanced blood-based test that harnesses artificial intelligence and machine learning. LungLB is designed to precisely identify and quantify circulating tumor cells (CTCs), ultimately aiming to minimize manual intervention and elevate diagnostic performance. The organization, which was previously known as Cynvenio Biosystems, Inc., adopted the LungLife AI, Inc. moniker in May of 2019. Its operations are based in Thousand Oaks, California.

Peers

Recent News

  • No recent news available.

Related

Browse more tickers: sitemap